Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg with Daunorubicin and Cytarabine in Relapsed AML
NCT02182596Phase 2Completed
- Sponsor
- Acute Leukemia French Association
- Start
- Jun 2006
- Primary completion
- Sep 2007
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Acute Leukemia French Association. Started Jun 2006; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02182596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182596.